Prevalence of childhood cancer survivors increasing
the ONA take:
According to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention, researchers have found that the prevalence of childhood cancer survivors is increasing, and most of those who have survived at least 5 years beyond diagnosis may have at least one comorbidity.
Using nine U.S. Surveillance, Epidemiology, and End Results (SEER) registries and data from the Childhood Cancer Survivor Study (CCSS), researchers estimated that there are 388,501 childhood cancer survivors in the United States, an increase of nearly 60,000 from the previous 2005 National Cancer Institute estimate.
Researchers found that approximately 84% of survivors have survived 5 or more years since diagnosis. The study also showed that about 70% of childhood cancer survivors have a mild or moderate chronic condition and about 32% have a severe, disabling, or life-threatening chronic condition.
The findings suggest that more needs to be done to effectively decrease morbidity burden in childhood cancer survivors, particularly those with neurocognitive dysfunction, self-reported functional impairment, activity limitations, impaired mental health, pain, or anxiety and fear.
Prevalence of childhood cancer survivors is increasing, and those who survived at least 5 years beyond diagnosis have at least one comorbidity.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|